The comparison of procalcitonin guidance administer antibiotics with empiric antibiotic therapy in critically ill patients admitted in intensive care unit

Acta Medica Iranica

Volumn 53, Issue 9, 2015, Pages 562-567

  Najafi, Atabak ^a   Khodadadian, Ali ^a   Sanatkar, Mehdi ^a   Moharari, Reza Shariat ^a   Etezadi, Farhad ^a   Ahmadi, Arezoo ^a   Imani, Farsad ^a   Khajavi, Mohammad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibiotics; Intensive care unit; Procalcitonin; Systemic inflammation syndrome

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTERIAL INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; EMPIRIC ANTIBIOTIC THERAPY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SINGLE BLIND PROCEDURE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; AGED; BLOOD; CRITICAL ILLNESS; HOSPITAL ADMISSION; LENGTH OF STAY; MIDDLE AGED; ORGAN DYSFUNCTION SCORE; SEPSIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOMARKERS; CALCITONIN; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; ORGAN DYSFUNCTION SCORES; PATIENT ADMISSION; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SEPSIS; SINGLE-BLIND METHOD; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84943610054     PISSN: 00446025     EISSN: 17359694     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Calandra T, Cohen J. International Sepsis Forum Definition of Infection in the ICU Consensus Conference. Crit Care Med 2005;33(7):1538-48.
2. Evans HL, Lefrak SN, Lyman J, et al. Cost of Gramnegative resistance. Crit Care Med 2007;35(1):89-95.
3. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Chest 2009;136(5 Suppl):e28.
4. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for the management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34(1):17-60.
5. Harbarth S, Garbino J, Pugin J, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003;115(7):529-35.
6. Bergmans DC, Bonten MJ, Gaillard CA, et al. Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother 1999;39(4):527-35.
7. Brunkhorst FM, Wegscheider K, Forycki ZF, et al. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 2000;26(Suppl 2): S148-52.
8. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006;34(7):1996-2003.
9. Reinhart K, Meisner M, Brunkhorst FM. Markers for sepsis diagnosis: what is useful? Crit Care Clin 2006;22(3):503-19.
10. Meynaar IA, Droog W, Batstra M, et al. In Critically Ill Patients, Serum Procalcitonin Is More Useful in Differentiating between Sepsis and SIRS than CRP, Il-6, or LBP. Crit Care Res Pract 2011;2011:594645.
11. Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with communityacquired pneumonia: a prospective cohort trial. Chest 2010;138(1):121-9.
12. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174(1):84-93.
13. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: clusterrandomised, single-blinded intervention trial. Lancet 2004;363(9409):600-7.
14. Müller B, Becker KL, Schächinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000;28(4):977-83.
15. Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis 2007;44(1):87-93.
16. Harbarth S. Nosocomial transmission of antibiotic-resistant microorganisms. Curr Opin Infect Dis 2001;14(4):437-42.
17. Reinhart K, Meisner M, Brunkhorst FM. Markers for sepsis diagnosis: what is useful? Crit Care Clin 2006;22(3):503-19.
18. Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39(2):206-17.
19. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006;34(7):1996-2003.
20. Li H, Luo YF, Blackwell TS, et al. Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections. Antimicrob Agents Chemother 2011;55(12):5900-6.
21. Fazili T, Endy T, Javaid W, et al. Role of procalcitonin in guiding antibiotic therapy. Am J Health Syst Pharm 2012;69(23):2057-61.
22. Póvoa P, Salluh JI. Biomarker-guided antibiotic therapy in adult critically ill patients: a critical review. Ann Intensive Care 2012;2(1):32.
23. Fazili T, Endy T, Javaid W, et al. Role of procalcitonin in guiding antibiotic therapy. Am J Health Syst Pharm 2012;69(23):2057-61.
24. Tang J, Long W, Yan L, et al. Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial. BMC Infect Dis 2013;13:596.
25. Prkno A, Wacker C, Brunkhorst FM, et al. Procalcitoninguided therapy in intensive care unit patients with severe sepsis and septic shock-a systematic review and metaanalysis. Crit Care 2013;17(6):R291.
26. Charles PE, Kus E, Aho S, et al. Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report. BMC Infect Dis 2009;9(1):49.
27. Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008;177(5):498-505.
28. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: clusterrandomised, single-blinded intervention trial. Lancet 2004;363(9409):600-7.
29. Harbarth S, Albrich WC, Müller B. When once is not enough--further evidence of procalcitonin-guided antibiotic stewardship. Crit Care 2009;13(4):165.
30. Marik PE. The clinical features of severe communityacquired pneumonia presenting as septic shock. Norasept II Study Investigators. J Crit Care 2000;15(3):85-90.